<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="et al., 2020). The symptoms include fever, dry cough, fatigue," exact="shortness" post="of breath, chills, muscles pain, headache, gastric disturbances and"/>
 <result pre="due to prior exposure, reducing the efficacy. •May lead to" exact="cancer" post="due to the integration of the viral genome into"/>
 <result pre="FluGen | Bharat Biotech) M2SR, a self-limiting version of the" exact="influenza" post="virus, which is modified by insertion of the SARS-CoV-2"/>
 <result pre="protein. Furthermore, the vaccine expresses the hemagglutinin protein of the" exact="influenza" post="virus, thereby inducing immune response against both the viruses."/>
 <result pre="cells. It is potentially more immunogenic than the wild type" exact="influenza" post="virus and can be administered as a nasal spray"/>
 <result pre="antagonist, NS1, which is potentially more immunogenic than the wild-type" exact="influenza" post="virus.&quot; 10 CoroFlu, self-limiting influenza virus (M2SR)Non-replicating Viral Vector/"/>
 <result pre="more immunogenic than the wild-type influenza virus.&quot; 10 CoroFlu, self-limiting" exact="influenza" post="virus (M2SR)Non-replicating Viral Vector/ (Anon, 2020e; Anon, 2020c) University"/>
 <result pre="be administered via the nasal route. 11 Replicating viral vector/" exact="measles" post="vector/West Nile, CHIKV, Ebola, Lassa, Zika, MERS/ (Campbell, 2020;"/>
 <result pre="(Campbell, 2020; Anon, 2020c) The Institut Pasteur Pre-Clinical The proprietary" exact="measles" post="vector (MV) technology is chosen to develop the vaccine"/>
 <result pre="to protect against other infectious agents. 3 Live attenuated recombinant" exact="measles" post="virus (rMV)/ (Anon, 2020s; Anon, cc; Anon, 2020t) ZydusCadila"/>
 <result pre="developers. They are working on DNA vaccines, live attenuated recombinant" exact="measles" post="vaccines, inactivated viral vaccines, subunit vaccines, and the vaccines"/>
 <result pre="AhnJ.Y.SohnY.LeeS.H.Use of convalescent plasma therapy in two covid‐19 patients with" exact="acute respiratory distress syndrome" post="in KoreaJ Korean Med Sci.202010.3346/jkms.2020.35.e149 AnonCountries where COVID-19 has"/>
 <result pre="DoremalenNeeltje vanLambeTeresaSpencerAlexandraBelij-RammerstorferSandraPurushothamJyothi N.PortJulia R.AvanzatoVictoriaBushmakerTrentonFlaxmanAmyUlaszewskaMartaFeldmannFriederikeAllenElizabeth R.SharpeHannahJonathan ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2" exact="pneumonia" post="in rhesus macaquess.l. : bioRxiv202010.1101/2020.05.13.093195 DorpLucy vanAcmanMislavRichardDamienShawLiam P.FordCharlotte E.OrmondLouiseOwenChristopher"/>
 <result pre="— Preliminary ReportN Engl J Med.July2020 JiangS.DuL.ShiZ.An emerging coronavirus causing" exact="pneumonia" post="outbreak in Wuhan, China: calling for developing therapeutic and"/>
 <result pre="with SARS-CoVNat Commun162020201110.1038/s41467-020-15562-9 ParkSu EunEpidemiology, virology, and clinical features of" exact="severe acute respiratory syndrome" post="-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)Clin Exp Pediatr202011912410.3345/cep.2020.0049332252141 Pharmaceutical Targeting the"/>
 <result pre="the Future2018[Online] October 11, 2018. https://www.infectioncontroltoday.com/public-health/100-years-after-spanish-flu-lessons-learned-and-challenges-futurehttps://www.infectioncontroltoday.com/ ShangW.YangY.RaoY.The outbreak of SARS-CoV-2" exact="pneumonia" post="calls for viral vaccinesNPJ Vaccines202010.1038/s41541-020-0170-0 ShenChenguangTreatment of 5 Critically"/>
</results>
